Molecular markers relating to malignant progression in Grade II astrocytoma

Yue, Wei; Yu, Su Huan; Zhao, Shiqi; Chen, Zhong Ping

doi:10.3171/2008.3.jns17459

Cited by 12 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Authors of several recent studies have examined the histological grade and molecular alterations in order to identify biomarkers for predicting malignant progression. In a study of 33 WHO grade II astrocytomas by Yue et al [15], expression of Ki-67 was significantly associated with malignant progression, suggesting that tumors expressing higher Ki-67 may have an inherently faster growth rate and thus recur faster in the setting of gross-total or subtotal resection. Ishii et al reported that the presence of TP53 mutation in WHO Grade II astrocytoma was associated with malignant progression and shorter PFS, whereas tumors without TP53 mutation recurred and progressed to malignancy without the change in TP53 status [16].…”

Section: Discussionmentioning

confidence: 99%

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival

Chan

Qin

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

Recurrence and progression to higher grade lesions are characteristic behaviorsof gliomas. Though IDH1 mutation frequently occurs and is considered as an early event in gliomagenesis, little is known about its role in the recurrence and progression of gliomas. We therefore analysed IDH1 and IDH2 statusat codon 132 of IDH1 and codon 172 of IDH2 by direct sequencing and anti-IDH1-R132H immunohistochemistry in 53 paired samples and their recurrences, including 29 low- grade gliomas, 16 anaplastic gliomas and 8 Glioblastomas. IDH1/IDH2 mutation was detected in 32 primarytumors, with 25 low- grade gliomas and 6 anaplastic gliomas harboring IDH1 mutation and 1 low- grade glioma harboring IDH2 mutation. All of the paired tumors showed consistent IDH1 and IDH2 status. Patients were analyzed according to IDH1 status and tumor-related factors. Malignant progression at recurrence was noted in 22 gliomas and was not associated with IDH1 mutation. Survival analysis revealed patients with IDH1 mutated gliomas had a significantly longer progression-free survival (PFS) and overall survival (OS). In conclusion, this study demonstrated a strong tendency of IDH1/IDH2 status being consistent during progression of glioma. IDH1 mutation was not a predictive marker for malignant progression and it was a potential prognostic marker for gliomas of Chinese patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival

Chan

Qin

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…2,3 Owing to the indistinct symptoms and lack of an effective diagnostic method for early detection, patients with GC are typically diagnosed at an advanced stage and have a dismal prognosis. 5,6 Taking this into consideration, it is necessary to seek more effective biological markers for the diagnosis and treatment of GC. 5,6 Taking this into consideration, it is necessary to seek more effective biological markers for the diagnosis and treatment of GC.…”

Section: Introductionmentioning

confidence: 99%

Retracted: Knockdown of long noncoding RNA urothelial carcinoma–associated 1 inhibits cell viability, migration, and invasion by regulating microRNA‐182 in gastric carcinoma

Qin

Jia

Xie

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…They found that overexpression of TP53 protein was related to malignant progression. In our previous study, we reported TP53 overexpression and mutation as molecular markers to predict malignant progression in astrocytomas[19]. However, the role of TP53 in predicting prognosis for LGGs is controversial.…”

Section: Discussionmentioning

confidence: 99%

Long-term molecular changes in WHO grade II astrocytomas following radiotherapy

Yue¹,

Sai

Wu³

et al. 2012

Chin J Cancer

Self Cite

View full text Add to dashboard Cite

Monitoring the long-term radiotherapy-associated molecular changes in low-grade gliomas (LGGs) facilitates the understanding of LGG response to radiotherapy. In this study, we used immunohistochemistry to analyze the expression of Ki-67, tumor protein P53 (TP53), P21, and P27 in 8 paired WHO grade II astrocytoma samples. The interval between radiotherapy (RT) and the second surgery was more than 3 months in all cases. The average Ki-67 labeling index (LI) was 5.3% in pre-RT samples and 11.54% in post-RT samples. Ki-67 LI was higher in the primary tumors that underwent malignant transformation observed at the second surgery after radiation. Post-RT Ki-67 LI decreased in 2 cases with an interval of less than 12 months between RT and the second surgery. TP53 expression was found in 3 out of 4 pre-RT samples with malignant transformation and in 1 out of 4 pre-RT samples without malignant transformation. Post-RT TP53 increased in 2 cases in which increased expression of P21 or P27 was also observed. Our study suggests that radiotherapy can inhibit WHO grade II astrocytoma proliferation as reflected by Ki-67 LI, but the effect attenuates with time. In addition, there is a tendency of malignant transformation for WHO grade II astrocytomas with a high Ki-67 level or TP53 expression in initial samples.

show abstract

Molecular markers relating to malignant progression in Grade II astrocytoma

Abstract: Overexpression of TP53, TP53 mutation, and Ki 67 labeling index could be molecular markers in astrocytomas predicting malignant progression.

Cited by 12 publications

References 10 publications

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival

Retracted: Knockdown of long noncoding RNA urothelial carcinoma–associated 1 inhibits cell viability, migration, and invasion by regulating microRNA‐182 in gastric carcinoma

Long-term molecular changes in WHO grade II astrocytomas following radiotherapy

Contact Info

Product

Resources

About